PRAXPraxis Precision Medicines, Inc.
Pharmaceutical Preparations
- Revenue
- $0
- 100% YoY
- Operating margin
- —
- EBITDA
- −$326M
- 63% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear—Over 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | — | $0 | $2M | $9M | $0 | 100% |
| Operating income | −$167M | −$215M | −$126M | −$200M | −$326M | 63% |
| Net income | −$167M | −$214M | −$123M | −$183M | −$303M | 66% |
| Operating cash flow | −$125M | −$185M | −$111M | −$132M | −$249M | 89% |
| Capex | $1M | $444K | $50K | $0 | $56K | |
| Stock-based comp | $23M | $29M | $25M | $41M | $34M | 18% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $9M | $56M | 36 | 125 |
| FY2024 | $13M | $21M | 9 | 93 |
| FY2023 | $2M | $1M | 3 | 94 |
| FY2022 | $6M | −$18M | 4 | 90 |
| FY2021 | $11M | −$62M | 36 | 100 |